Symbol
| CYP24A1
| contributors: mct - updated : 29-04-2014
|
HGNC name
| cytochrome P450, family 24, subfamily A, polypeptide 1
|
HGNC id
| 2602
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in lung tumors restricts 1,25D3 activity and support the preclinical evaluation of CYP24 inhibitors for lung cancer treatment | tumoral
|  
|  
| --over
|  
|
in renal cell carcinoma | constitutional
| germinal mutation
|  
|  
|  
|
bi-allelic mutations in CYP24A1 causes elevated serum vitamin D, hypercalciuria, nephrocalcinosis, and renal stones | |
Susceptibility
|
to vitamin D response variation in postmenopausal women |
Variant & Polymorphism
other
| DNA methylation levels of CYP24A1 predict vitamin D response variation in postmenopausal women |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | digestive | colon | |
selective inhibition of CYP24A1 may be a new approach for enhancement of the anti-tumor effect of 1,25-D3 on colorectal cancer |
| | | |
| in fracture repair, delay in the mineralization of the cartilaginous matrix of the soft callus in Cyp24a1 -/- mutant animals, accompanied by reduced expression of chondrocyte marker genes |